483
Parvez MantryParvez Mantry – FDA 483, Nov 14, 2023
Record Details
An FDA inspection of The Liver Institute at Methodist Dallas, a clinical investigator site, revealed a significant deficiency in their investigational plan. The firm failed to report Serious Adverse Events (SAEs) to the sponsor or designee within the required 24-hour timeframe, as stipulated by their own protocol. This lapse in timely reporting was observed across multiple study subjects, indicating a failure to adhere to critical safety reporting procedures.
View Company Profile
ID · 2120ba30-a661-48c1-a43e-9525f78d5fb7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.